{"id":"indinavir","rwe":[{"pmid":"41876751","year":"2026","title":"Predictive modeling of influenza strain drugs using temperature-based topological indices and regression analysis via multi-criteria decision making techniques.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41693863","year":"2025","title":"From virtual screening to animal models: chlorhexidine and indinavir as promising anti-Zika drug candidates.","finding":"","journal":"Frontiers in cellular and infection microbiology","studyType":"Clinical Study"},{"pmid":"41167447","year":"2026","title":"Structure-based drug repurposing and experimental validation of inhibitors targeting LigaseD from Mycobacterium tuberculosis.","finding":"","journal":"Archives of biochemistry and biophysics","studyType":"Clinical Study"},{"pmid":"41151410","year":"2025","title":"Metabolic reprogramming of hippocampal endothelial cells contributes to blood-brain barrier dysfunction in perioperative neurocognitive disorder.","finding":"","journal":"Biochemical and biophysical research communications","studyType":"Clinical Study"},{"pmid":"41019617","year":"2025","title":"Insights into Antiviral Candidates against Oropouche Virus: A Molecular Dynamics Study.","finding":"","journal":"ACS physical chemistry Au","studyType":"Clinical Study"}],"tags":[{"label":"indinavir","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 3A4","category":"target"},{"label":"CYP3A4","category":"gene"},{"label":"SLC47A1","category":"gene"},{"label":"TACR2","category":"gene"},{"label":"J05AE02","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Human immunodeficiency virus infection","category":"indication"},{"label":"Merck Sharp Dohme","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-HIV Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Retroviral Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"HIV Protease Inhibitors","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"},{"label":"Viral Protease Inhibitors","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":1018.5,"date":"","count":177,"signal":"Lipodystrophy acquired","source":"DrugCentral FAERS","actionTaken":"Reported 177 times (LLR=1018)"},{"llr":840.059,"date":"","count":140,"signal":"Mitochondrial toxicity","source":"DrugCentral FAERS","actionTaken":"Reported 140 times (LLR=840)"},{"llr":648.682,"date":"","count":142,"signal":"Eyelid ptosis","source":"DrugCentral FAERS","actionTaken":"Reported 142 times (LLR=649)"},{"llr":507.117,"date":"","count":81,"signal":"Progressive external ophthalmoplegia","source":"DrugCentral FAERS","actionTaken":"Reported 81 times (LLR=507)"},{"llr":465.438,"date":"","count":139,"signal":"Diplopia","source":"DrugCentral FAERS","actionTaken":"Reported 139 times (LLR=465)"},{"llr":429.951,"date":"","count":93,"signal":"Viral mutation identified","source":"DrugCentral FAERS","actionTaken":"Reported 93 times (LLR=430)"},{"llr":399.817,"date":"","count":94,"signal":"Virologic failure","source":"DrugCentral FAERS","actionTaken":"Reported 94 times (LLR=400)"},{"llr":324.858,"date":"","count":89,"signal":"Pathogen resistance","source":"DrugCentral FAERS","actionTaken":"Reported 89 times (LLR=325)"},{"llr":216.717,"date":"","count":83,"signal":"Drug resistance","source":"DrugCentral FAERS","actionTaken":"Reported 83 times (LLR=217)"},{"llr":152.639,"date":"","count":34,"signal":"Ophthalmoplegia","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=153)"},{"llr":130.085,"date":"","count":40,"signal":"Blood lactic acid increased","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=130)"},{"llr":118.035,"date":"","count":38,"signal":"Hypertriglyceridaemia","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=118)"},{"llr":105.069,"date":"","count":32,"signal":"Multiple-drug resistance","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=105)"},{"llr":104.352,"date":"","count":63,"signal":"Foetal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=104)"},{"llr":101.81,"date":"","count":53,"signal":"Nephrolithiasis","source":"DrugCentral FAERS","actionTaken":"Reported 53 times (LLR=102)"}],"drugInteractions":[{"url":"/drug/cyp3a4-substrates","drug":"CYP3A4 Substrates","action":"Use caution","effect":"Strong CYP3A4 Inhibitors - CYP3A4 Substrates","source":"DrugCentral","drugSlug":"cyp3a4-substrates"},{"url":"/drug/alfentanil","drug":"alfentanil","action":"Avoid combination","effect":"May interact with Alfentanil, Indinavir Sulfate","source":"DrugCentral","drugSlug":"alfentanil"},{"url":"/drug/bosentan","drug":"bosentan","action":"Monitor closely","effect":"May interact with Bosentan, Indinavir Sulfate","source":"DrugCentral","drugSlug":"bosentan"},{"url":"/drug/crizotinib","drug":"crizotinib","action":"Monitor closely","effect":"May interact with Crizotinib, Indinavir Sulfate","source":"DrugCentral","drugSlug":"crizotinib"},{"url":"/drug/delavirdine","drug":"delavirdine","action":"Monitor closely","effect":"May interact with Delavirdine Mesylate, Indinavir Sulfate","source":"DrugCentral","drugSlug":"delavirdine"},{"url":"/drug/itraconazole","drug":"itraconazole","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Itraconazole","source":"DrugCentral","drugSlug":"itraconazole"},{"url":"/drug/ixabepilone","drug":"ixabepilone","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Ixabepilone","source":"DrugCentral","drugSlug":"ixabepilone"},{"url":"/drug/ketoconazole","drug":"ketoconazole","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Ketoconazole","source":"DrugCentral","drugSlug":"ketoconazole"},{"url":"/drug/lovastatin","drug":"lovastatin","action":"Avoid combination","effect":"May interact with Indinavir Sulfate, Lovastatin","source":"DrugCentral","drugSlug":"lovastatin"},{"url":"/drug/maraviroc","drug":"maraviroc","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Maraviroc","source":"DrugCentral","drugSlug":"maraviroc"},{"url":"/drug/methylergometrine","drug":"methylergometrine","action":"Avoid combination","effect":"May interact with Indinavir Sulfate, Methylergonovine","source":"DrugCentral","drugSlug":"methylergometrine"},{"url":"/drug/methysergide","drug":"methysergide","action":"Avoid combination","effect":"May interact with Indinavir Sulfate, Methysergide","source":"DrugCentral","drugSlug":"methysergide"},{"url":"/drug/midazolam","drug":"midazolam","action":"Avoid combination","effect":"May interact with Indinavir Sulfate, Midazolam","source":"DrugCentral","drugSlug":"midazolam"},{"url":"/drug/omeprazole","drug":"omeprazole","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Omeprazole","source":"DrugCentral","drugSlug":"omeprazole"},{"url":"/drug/quinidine","drug":"quinidine","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Quinidine","source":"DrugCentral","drugSlug":"quinidine"},{"url":"/drug/ranolazine","drug":"ranolazine","action":"Avoid combination","effect":"May interact with Indinavir Sulfate, Ranolazine","source":"DrugCentral","drugSlug":"ranolazine"},{"url":"/drug/rifabutin","drug":"rifabutin","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Rifabutin","source":"DrugCentral","drugSlug":"rifabutin"},{"url":"/drug/rifampicin","drug":"rifampicin","action":"Avoid combination","effect":"May interact with Indinavir Sulfate, Rifampin","source":"DrugCentral","drugSlug":"rifampicin"},{"url":"/drug/rifapentine","drug":"rifapentine","action":"Avoid combination","effect":"May interact with Indinavir Sulfate, Rifapentine","source":"DrugCentral","drugSlug":"rifapentine"},{"url":"/drug/sildenafil","drug":"sildenafil","action":"Monitor closely","effect":"May interact with Indinavir Sulfate, Sildenafil Citrate","source":"DrugCentral","drugSlug":"sildenafil"}],"commonSideEffects":[{"effect":"Abdominal pain","drugRate":"16.6%","severity":"serious"},{"effect":"Nausea","drugRate":"11.7%","severity":"common"},{"effect":"Diarrhea","drugRate":"3.3%","severity":"common"},{"effect":"Vomiting","drugRate":"8.4%","severity":"common"},{"effect":"Fever","drugRate":"1.5%","severity":"mild"},{"effect":"Malaise","drugRate":"2.1%","severity":"mild"},{"effect":"Asthenia/fatigue","drugRate":"2.1%","severity":"mild"},{"effect":"Back pain","drugRate":"8.4%","severity":"common"},{"effect":"Headache","drugRate":"5.4%","severity":"common"},{"effect":"Dizziness","drugRate":"3.0%","severity":"mild"},{"effect":"Somnolence","drugRate":"2.4%","severity":"mild"},{"effect":"Pruritus","drugRate":"4.2%","severity":"common"},{"effect":"Rash","drugRate":"1.2%","severity":"mild"},{"effect":"Cough","drugRate":"1.5%","severity":"mild"},{"effect":"Nephrolithiasis/urolithiasis","drugRate":"8.7%","severity":"serious"},{"effect":"Dysuria","drugRate":"1.5%","severity":"mild"},{"effect":"Taste perversion","drugRate":"2.7%","severity":"mild"},{"effect":"Jaundice","drugRate":"1.5%","severity":"mild"},{"effect":"Anemia","drugRate":"0.6%","severity":"mild"},{"effect":"Increased ALT","drugRate":"4.9%","severity":"serious"},{"effect":"Increased AST","drugRate":"3.7%","severity":"serious"},{"effect":"Increased serum amylase","drugRate":"2.1%","severity":"mild"},{"effect":"Increased glucose","drugRate":"0.9%","severity":"mild"},{"effect":"Increased creatinine","drugRate":"0%","severity":"unknown"}],"contraindications":["Blood in urine","Breastfeeding (mother)","Cirrhosis of liver","Diabetes mellitus","Disease of liver","Hemolytic anemia","Hemophilia","Hyperbilirubinemia","Hypercholesterolemia","Hyperglycemia","Hypertriglyceridemia","Kidney stone","Liver function tests abnormal","Pyuria"],"specialPopulations":{"Pregnancy":"The optimal dosing regimen for use of indinavir in pregnant patients has not been established. CRIXIVAN dose of 800 mg every hours (with zidovudine 200 mg every hours and lamivudine 150 mg twice day) has been studied in 16 HIV-infected pregnant patients at 14 to 28 weeks of gestation at enrollment (study PACTG 358). The mean indinavir plasma AUC0-8hr at weeks 30-32 of gestation (n=11) was 9231 nMohr, which is 74% (95% CI: 50%, 86%) lower than that observed weeks postpartum.","Geriatric use":"Clinical studies of CRIXIVAN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.","Paediatric use":"The optimal dosing regimen for use of indinavir in pediatric patients has not been established. In HIV-infected pediatric patients (age 4-15 years), dosage regimen of indinavir capsules, 500 mg/m2 every hours, produced AUC0-8hr of 38,742 +- 24,098 nMohour (n=34), Cmax of 17,181 +- 9809 nM (n=34), and trough concentrations of 134 +- 91 nM (n=28). The pharmacokinetic profiles of indinavir in pediatric patients were not comparable to profiles previously observed in HIV-infected adults","Hepatic impairment":"Patients with mild to moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of indinavir resulting in approximately 60% higher mean AUC following single 400-mg dose (n=12). The half-life of indinavir increased to 2.8 +- 0.5 hours. Indinavir pharmacokinetics have not been studied in patients with severe hepatic insufficiency."}},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[],"pricing":[],"allNames":"crixivan","offLabel":[],"synonyms":["indinavir","indinavir sulphate","crixivan","indinavir sulfate"],"timeline":[{"date":"1996-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MERCK SHARP DOHME to Merck Sharp Dohme"},{"date":"1996-03-13","type":"positive","source":"DrugCentral","milestone":"FDA approval (Merck Sharp Dohme)"}],"aiSummary":"Crixivan (indinavir) is a small molecule drug developed by Merck Sharp Dohme, targeting the Cytochrome P450 3A4 enzyme. It is an off-patent medication used to treat human immunodeficiency virus (HIV) infection, with a short half-life of 1.0 hours and moderate bioavailability of 65%. Although it is no longer patented, Crixivan remains a commercial product under the ownership of Merck Sharp Dohme. As an HIV protease inhibitor, it works by blocking the replication of the virus, preventing the production of new viral particles. Despite its off-patent status, Crixivan's commercial availability is limited due to the absence of generic manufacturers.","approvals":[{"date":"1996-03-13","orphan":false,"company":"MERCK SHARP DOHME","regulator":"FDA"}],"brandName":"Crixivan","ecosystem":[{"indication":"Human immunodeficiency virus infection","otherDrugs":[{"name":"abacavir","slug":"abacavir","company":"Viiv Hlthcare"},{"name":"amprenavir","slug":"amprenavir","company":"Glaxosmithkline"},{"name":"atazanavir","slug":"atazanavir","company":"Bristol Myers Squibb"},{"name":"bictegravir","slug":"bictegravir","company":"Gilead Sciences Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Cytochrome P450 3A4","novelty":"Follow-on","targets":[{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"},{"gene":"SLC47A1","source":"DrugCentral","target":"Multidrug and toxin extrusion protein 1","protein":"Multidrug and toxin extrusion protein 1"},{"gene":"TACR2","source":"DrugCentral","target":"Substance-K receptor","protein":"Substance-K receptor"},{"gene":"TBXAS1","source":"DrugCentral","target":"Thromboxane-A synthase","protein":"Thromboxane-A synthase"},{"gene":"SLC47A2","source":"DrugCentral","target":"Multidrug and toxin extrusion protein 2","protein":"Multidrug and toxin extrusion protein 2"}],"modality":"Small Molecule","drugClass":"indinavir","explanation":"Mechanism of Action:. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles.","oneSentence":"Crixivan blocks the replication of HIV by inhibiting the protease enzyme, which is essential for the virus to produce new particles.","technicalDetail":"Crixivan (indinavir) is a competitive inhibitor of the HIV-1 protease enzyme, which is essential for the maturation of viral particles. By binding to the active site of the protease enzyme, Crixivan prevents the cleavage of viral polyproteins, thereby inhibiting viral replication."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Indinavir","title":"Indinavir","extract":"Indinavir is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV/AIDS. It is soluble white powder administered orally in combination with other antiviral drugs. The drug prevents protease from functioning normally. Consequently, HIV viruses cannot reproduce, causing a decrease in the viral load. Commercially sold indinavir is indinavir anhydrous, which is indinavir with an additional amine in the hydroxyethylene backbone. This enhances its solubility and oral bioavailability, making it easier for users to intake. It was synthetically produced for the purpose of inhibiting the protease in the HIV virus.","wiki_history":"==History==\nThe official start to its development started in December 1986 when Merck's president, Edward Scolnick, announced that they would start a comprehensive AIDS research program. They started a laboratory dedicated to AIDS research in West Point, Pennsylvania and placed Emilio Emini in charge of the laboratory. A couple months later in January 1987, a team of researchers consisting of Emilio Emini, Joel Huff, and Irving Sigal, kickstarted their studies by basing their project off of earlier research on the protease enzyme, renin. They were the ones who started the process of research and development into protease inhibitors and its relation to the virus.  Over a year later, in July 1988, Nancy Kohl, Emilio Emini, et al., published in the Proceedings of the National Academy of the Science about the idea of inhibiting the protease. \n\nThe Food and Drug Administration (FDA) approved indinavir in March 1996, making it the eighth antiretroviral drug approved. It was first given its blessing by the FDA on March 1 then approved merely 42 days after the company filed the drug to the FDA. A major reason for this fast approval was the presentation Merck gave to the committee with results from Study 035 (see below). The fact that they had fast approval ran into trouble with groups like Treatment Action Group who thought that accelerated drug approval was not beneficial for people infected with HIV/AIDS.\n\nFrom then on, indinavir used with dual NRTIs set a new standard for treatment of HIV/AIDS. Protease inhibitors changed the nature of AIDS from a terminal illness to a somewhat manageable one. It significantly increased life expectancies and decreased noticeable symptoms from infectious diseases that were the result of a weakened immune system from the virus. Currently, it is being replaced by newer drugs that are more convenient to take, less likely to promote virus resistance, and less toxic, such as darunavir or atazanavir."},"commercial":{"launchDate":"1996","_launchSource":"DrugCentral (FDA 1996-03-13, MERCK SHARP DOHME)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1437","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=INDINAVIR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INDINAVIR","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Indinavir","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T13:56:56.469416","biosimilars":[],"competitors":[{"drugName":"saquinavir","drugSlug":"saquinavir","fdaApproval":"1995-12-06","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ritonavir","drugSlug":"ritonavir","fdaApproval":"1996-03-01","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nelfinavir","drugSlug":"nelfinavir","fdaApproval":"1997-03-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"amprenavir","drugSlug":"amprenavir","fdaApproval":"1999-04-15","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"fosamprenavir","drugSlug":"fosamprenavir","fdaApproval":"2003-10-20","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"atazanavir","drugSlug":"atazanavir","fdaApproval":"2003-06-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tipranavir","drugSlug":"tipranavir","fdaApproval":"2005-06-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"darunavir","drugSlug":"darunavir","fdaApproval":"2006-06-23","patentExpiry":"Jun 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nirmatrelvir","drugSlug":"nirmatrelvir","fdaApproval":"2023-05-25","relationship":"same-class"}],"genericName":"indinavir","indications":{"approved":[{"name":"Human immunodeficiency virus infection","source":"DrugCentral","snomedId":86406008,"regulator":"FDA","eligibility":{"Study 028":{"age":"adults","stage":"CD4 cell counts of 50 to 250 cells/mm3","biomarkers":"CD4 cell counts of 50 to 250 cells/mm3, HIV RNA of 4.44 log10 copies/mL (27,824 copies/mL)","prior treatment":"antiretroviral naive"},"Study 035":{"age":"adults","stage":"mean baseline CD4 count 175 cells/mm3","biomarkers":"mean baseline serum viral RNA 4.62 log10 copies/mL (41,230 copies/mL)","prior treatment":"zidovudine-experienced, protease-inhibitor- and lamivudine-naive"},"Study ACTG 320":{"age":"adults","stage":"CD4 cell counts of <=200 cells/mm3","biomarkers":"CD4 cell counts of <=200 cells/mm3, HIV RNA of 4.95 log10 copies/mL (89,035 copies/mL)","prior treatment":"zidovudine experienced"}}}],"offLabel":[{"name":"Prevention of HIV Infection after Exposure","source":"DrugCentral","drugName":"INDINAVIR","evidenceCount":34,"evidenceLevel":"moderate"}],"pipeline":[]},"currentOwner":"Merck Sharp Dohme","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"saquinavir","brandName":"saquinavir","genericName":"saquinavir","approvalYear":"1995","relationship":"same-class"},{"drugId":"ritonavir","brandName":"ritonavir","genericName":"ritonavir","approvalYear":"1996","relationship":"same-class"},{"drugId":"nelfinavir","brandName":"nelfinavir","genericName":"nelfinavir","approvalYear":"1997","relationship":"same-class"},{"drugId":"amprenavir","brandName":"amprenavir","genericName":"amprenavir","approvalYear":"1999","relationship":"same-class"},{"drugId":"fosamprenavir","brandName":"fosamprenavir","genericName":"fosamprenavir","approvalYear":"2003","relationship":"same-class"},{"drugId":"atazanavir","brandName":"atazanavir","genericName":"atazanavir","approvalYear":"2003","relationship":"same-class"},{"drugId":"tipranavir","brandName":"tipranavir","genericName":"tipranavir","approvalYear":"2005","relationship":"same-class"},{"drugId":"darunavir","brandName":"darunavir","genericName":"darunavir","approvalYear":"2006","relationship":"same-class"},{"drugId":"nirmatrelvir","brandName":"nirmatrelvir","genericName":"nirmatrelvir","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2,PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":["Acquired Immune Deficiency Syndrome (AIDS)","HIV Infections"],"enrollment":133,"completionDate":"2027-03"},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":["HIV"],"enrollment":224,"completionDate":"2018-09-21"},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":["HIV Infections"],"enrollment":1578,"completionDate":"2020-09-30"},{"nctId":"NCT05502341","phase":"PHASE2,PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":["HIV-1-infection"],"enrollment":689,"completionDate":"2028-07"},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":["HIV Infections"],"enrollment":500,"completionDate":"2024-09-12"},{"nctId":"NCT00003008","phase":"PHASE2","title":"Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-12-15","conditions":["Sarcoma"],"enrollment":33,"completionDate":""},{"nctId":"NCT00039741","phase":"PHASE2,PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":["HIV Infections"],"enrollment":266,"completionDate":"2010-03"},{"nctId":"NCT00000841","phase":"PHASE3","title":"A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":1750,"completionDate":"1997-06"},{"nctId":"NCT00000848","phase":"PHASE2","title":"The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":144,"completionDate":"1998-10"},{"nctId":"NCT00000892","phase":"NA","title":"A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"1999-08"},{"nctId":"NCT00001083","phase":"PHASE2","title":"Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":240,"completionDate":"2001-06"},{"nctId":"NCT00001084","phase":"PHASE2","title":"A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":500,"completionDate":"1997-12"},{"nctId":"NCT00001095","phase":"PHASE2","title":"A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":94,"completionDate":"1999-10"},{"nctId":"NCT00012519","phase":"PHASE1,PHASE2","title":"Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":29,"completionDate":"2005-07"},{"nctId":"NCT00001058","phase":"PHASE2","title":"A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Mycobacterium Avium-intracellulare Infection","HIV Infections"],"enrollment":246,"completionDate":"1999-01"},{"nctId":"NCT00001086","phase":"PHASE2","title":"A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"1999-09"},{"nctId":"NCT00027339","phase":"PHASE2","title":"Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":53,"completionDate":"2005-06"},{"nctId":"NCT00039975","phase":"PHASE1","title":"Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Cardiovascular Diseases","Hypertension"],"enrollment":32,"completionDate":"2004-04"},{"nctId":"NCT00006339","phase":"PHASE2","title":"Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00005762","phase":"NA","title":"Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-03","conditions":["HIV Infections"],"enrollment":90,"completionDate":"2004-05"},{"nctId":"NCT00001133","phase":"PHASE1","title":"Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":50,"completionDate":"2006-08"},{"nctId":"NCT00000877","phase":"PHASE1","title":"Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":31,"completionDate":"2000-10"},{"nctId":"NCT00000859","phase":"NA","title":"A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":1300,"completionDate":"2001-12"},{"nctId":"NCT00000914","phase":"NA","title":"A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":800,"completionDate":"2000-06"},{"nctId":"NCT00000916","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":399,"completionDate":"2004-08"},{"nctId":"NCT00000912","phase":"PHASE2","title":"A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":475,"completionDate":"2000-05"},{"nctId":"NCT00000896","phase":"NA","title":"A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":24,"completionDate":"2000-10"},{"nctId":"NCT00000944","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Pregnancy"],"enrollment":24,"completionDate":"2003-03"},{"nctId":"NCT00000850","phase":"PHASE2","title":"The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":108,"completionDate":"2003-12"},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":440,"completionDate":"2003-06"},{"nctId":"NCT00000861","phase":"NA","title":"The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":1900,"completionDate":"1997-03"},{"nctId":"NCT00000901","phase":"PHASE1","title":"Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":24,"completionDate":"2000-10"},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":["ADHD","HIV"],"enrollment":127,"completionDate":"2016-07"},{"nctId":"NCT00411996","phase":"PHASE1,PHASE2","title":"The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2006-12","conditions":["HIV Infections","Tuberculosis"],"enrollment":20,"completionDate":"2009-12"},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":["HIV Infections"],"enrollment":675,"completionDate":"2009-12"},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":["HIV-DDI"],"enrollment":40,"completionDate":"2016-12-07"},{"nctId":"NCT00001644","phase":"PHASE1","title":"Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1997-03-03","conditions":["HIV Infection"],"enrollment":42,"completionDate":"2010-02-17"},{"nctId":"NCT00050180","phase":"PHASE4","title":"Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2002-11-22","conditions":["Healthy","HIV Infections"],"enrollment":81,"completionDate":"2007-08-24"},{"nctId":"NCT00541463","phase":"PHASE2","title":"A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-01","conditions":["HIV Infections"],"enrollment":330,"completionDate":"2003-05"},{"nctId":"NCT00000875","phase":"NA","title":"Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":16,"completionDate":"2003-04"},{"nctId":"NCT00000804","phase":"NA","title":"A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":"2002-08"},{"nctId":"NCT01067690","phase":"PHASE2","title":"Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Barbara Ensoli, MD, PhD","startDate":"2008-06","conditions":["Kaposi's Sarcoma"],"enrollment":25,"completionDate":"2016-06"},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":["HIV Infections"],"enrollment":192,"completionDate":"2015-03"},{"nctId":"NCT00477048","phase":"PHASE2","title":"Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2004-05","conditions":["IDV Associated Nephrotoxicity"],"enrollment":30,"completionDate":"2008-05"},{"nctId":"NCT00626301","phase":"PHASE4","title":"Lopinavir/Ritonavir Monotherapy in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-11","conditions":["HIV Infections"],"enrollment":40,"completionDate":"2009-09"},{"nctId":"NCT02300623","phase":"PHASE4","title":"Intermittent ART in Primary HIV Infection","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2000-03","conditions":["HIV"],"enrollment":12,"completionDate":"2013-04"},{"nctId":"NCT00000922","phase":"NA","title":"A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":1710,"completionDate":"2006-06"},{"nctId":"NCT00148785","phase":"PHASE4","title":"A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-07","conditions":["HIV Infections"],"enrollment":15,"completionDate":"2007-01"},{"nctId":"NCT00000874","phase":"","title":"A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1997-08","conditions":["HIV Infections"],"enrollment":148,"completionDate":"1999-03"},{"nctId":"NCT00006154","phase":"PHASE3","title":"A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":165,"completionDate":""},{"nctId":"NCT00637637","phase":"PHASE2","title":"External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases","status":"UNKNOWN","sponsor":"Oncology Institute of Southern Switzerland","startDate":"2007-09","conditions":["Cancer"],"enrollment":60,"completionDate":""},{"nctId":"NCT00000882","phase":"PHASE2","title":"Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":""},{"nctId":"NCT00016601","phase":"NA","title":"Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-06","conditions":["HIV Infections"],"enrollment":76,"completionDate":"2004-05"},{"nctId":"NCT00001566","phase":"PHASE2","title":"A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-12","conditions":["Ewing's Sarcoma","Rhabdomyosarcoma"],"enrollment":42,"completionDate":"2008-09"},{"nctId":"NCT00000919","phase":"NA","title":"A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":900,"completionDate":"2002-11"},{"nctId":"NCT00000903","phase":"PHASE3","title":"Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":444,"completionDate":"2001-07"},{"nctId":"NCT00000870","phase":"PHASE2","title":"A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":200,"completionDate":"2007-03"},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"2002-02"},{"nctId":"NCT00000923","phase":"NA","title":"Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":110,"completionDate":"2004-08"},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":["HIV-Associated Lipodystrophy Syndrome","Cardiovascular Disease"],"enrollment":80,"completionDate":"2007-12"},{"nctId":"NCT00002371","phase":"PHASE3","title":"The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1996-06","conditions":["HIV Infections"],"enrollment":80,"completionDate":"1997-12"},{"nctId":"NCT00001119","phase":"NA","title":"Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-10","conditions":["HIV Infections"],"enrollment":288,"completionDate":""},{"nctId":"NCT00006443","phase":"NA","title":"Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":24,"completionDate":""},{"nctId":"NCT00197639","phase":"","title":"Pharmacokinetic Study of Indinavir Drug Levels When Boosted With Ritonavir in Thailand","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2006-09","conditions":["HIV Infection"],"enrollment":19,"completionDate":"2010-08"},{"nctId":"NCT00259727","phase":"","title":"The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-01","conditions":["Diabetes","HIV Infections","Insulin Resistance"],"enrollment":80,"completionDate":"2008-09"},{"nctId":"NCT00002223","phase":"NA","title":"A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients","status":"COMPLETED","sponsor":"Abbott","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00158405","phase":"PHASE3","title":"Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-12","conditions":["HIV Infections"],"enrollment":840,"completionDate":"2006-12"},{"nctId":"NCT00362310","phase":"PHASE2","title":"Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir","status":"COMPLETED","sponsor":"Istituto Superiore di Sanità","startDate":"2003-06","conditions":["Classical Kaposi's Sarcoma"],"enrollment":28,"completionDate":"2007-07"},{"nctId":"NCT00001353","phase":"","title":"Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin Pairs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1993-03","conditions":["Acquired Immunodeficiency Syndrome","HIV Infection"],"enrollment":24,"completionDate":"2002-03"},{"nctId":"NCT00001443","phase":"PHASE1","title":"A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-07","conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"enrollment":63,"completionDate":"2000-10"},{"nctId":"NCT00011635","phase":"PHASE1","title":"The Effect of Milk Thistle on the Pharmacokinetics of Indinavir","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2001-02","conditions":["HIV Infection","Healthy"],"enrollment":20,"completionDate":"2001-06"},{"nctId":"NCT00002168","phase":"NA","title":"A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":["HIV Infections"],"enrollment":200,"completionDate":""},{"nctId":"NCT00002369","phase":"NA","title":"A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":["HIV Infections"],"enrollment":200,"completionDate":""},{"nctId":"NCT00120783","phase":"PHASE2","title":"Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance","status":"TERMINATED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-02","conditions":["HIV Infections"],"enrollment":40,"completionDate":"2003-08"},{"nctId":"NCT00122590","phase":"NA","title":"Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)","status":"TERMINATED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-07","conditions":["HIV Infections"],"enrollment":115,"completionDate":"2005-03"},{"nctId":"NCT00002241","phase":"PHASE2","title":"Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily","status":"UNKNOWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":80,"completionDate":""},{"nctId":"NCT00002361","phase":"PHASE2","title":"Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":30,"completionDate":""},{"nctId":"NCT00002208","phase":"PHASE3","title":"A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":400,"completionDate":""},{"nctId":"NCT00002452","phase":"PHASE2","title":"A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":30,"completionDate":""},{"nctId":"NCT00002379","phase":"PHASE2","title":"The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":["HIV Infections"],"enrollment":100,"completionDate":""},{"nctId":"NCT00002407","phase":"NA","title":"A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002451","phase":"PHASE2","title":"Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"UNKNOWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":8,"completionDate":""},{"nctId":"NCT00002410","phase":"PHASE3","title":"A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients","status":"COMPLETED","sponsor":"Dupont Merck","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002351","phase":"PHASE1","title":"A Study of L-735,524 in HIV-Positive Children and Adolescents","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":12,"completionDate":""},{"nctId":"NCT00002442","phase":"PHASE2","title":"A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-06","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00005118","phase":"PHASE2","title":"The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment","status":"UNKNOWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":100,"completionDate":""},{"nctId":"NCT00002386","phase":"PHASE4","title":"Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections","Hemophilia A"],"enrollment":55,"completionDate":""},{"nctId":"NCT00002354","phase":"NA","title":"A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":540,"completionDate":""},{"nctId":"NCT00002376","phase":"PHASE4","title":"The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":540,"completionDate":""},{"nctId":"NCT00002424","phase":"PHASE2","title":"A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine","status":"SUSPENDED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":186,"completionDate":""},{"nctId":"NCT00002179","phase":"PHASE4","title":"The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":200,"completionDate":""},{"nctId":"NCT00002400","phase":"NA","title":"A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":45,"completionDate":""},{"nctId":"NCT00002236","phase":"NA","title":"A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":["HIV Infections"],"enrollment":32,"completionDate":""},{"nctId":"NCT00002387","phase":"NA","title":"The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":80,"completionDate":""},{"nctId":"NCT00002220","phase":"PHASE3","title":"Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":120,"completionDate":""},{"nctId":"NCT00002423","phase":"PHASE2","title":"A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-03","conditions":["HIV Infections"],"enrollment":100,"completionDate":""},{"nctId":"NCT00002155","phase":"NA","title":"A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["HIV Infections"],"enrollment":600,"completionDate":""},{"nctId":"NCT00002202","phase":"PHASE3","title":"A Comparison of 141W94 and Indinavir in HIV-Infected Patients","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":460,"completionDate":""},{"nctId":"NCT00002393","phase":"PHASE3","title":"A Study of Indinavir Taken With or Without DMP 266","status":"COMPLETED","sponsor":"Dupont Merck","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":""},{"nctId":"NCT00002209","phase":"PHASE1","title":"Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy","status":"COMPLETED","sponsor":"Centaur Pharmaceuticals","startDate":"","conditions":["AIDS Dementia Complex","HIV Infections"],"enrollment":48,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"CRIXIVAN"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000022031","MMSL":"4875","NDDF":"005733","UNII":"5W6YA9PKKH","VUID":"4024026","CHEBI":"CHEBI:44032","VANDF":"4020965","RXNORM":"114289","UMLSCUI":"C0376637","ChEMBL_ID":"CHEMBL115","KEGG_DRUG":"D00897","DRUGBANK_ID":"DB00224","PDB_CHEM_ID":" MK1","PUBCHEM_CID":"5362440","SNOMEDCT_US":"108695003","IUPHAR_LIGAND_ID":"12684","SECONDARY_CAS_RN":"157810-81-6","MESH_DESCRIPTOR_UI":"D019469"},"formularyStatus":[],"originalProduct":{"form":"CAPSULE","route":"ORAL","company":"Merck Sharp & Dohme Corp.","brandName":"CRIXIVAN","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1996-","companyName":"Merck & Co.","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.0 hours","clearance":"18.0 mL/min/kg","bioavailability":"65%","fractionUnbound":"0.36%","volumeOfDistribution":"0.82 L/kg"},"publicationCount":2344,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AE02","allCodes":["J05AE02"]},"biosimilarFilings":[],"originalDeveloper":"Merck Sharp Dohme","recentPublications":[{"date":"2026 Mar 24","pmid":"41876751","title":"Predictive modeling of influenza strain drugs using temperature-based topological indices and regression analysis via multi-criteria decision making techniques.","journal":"Scientific reports"},{"date":"2025","pmid":"41693863","title":"From virtual screening to animal models: chlorhexidine and indinavir as promising anti-Zika drug candidates.","journal":"Frontiers in cellular and infection microbiology"},{"date":"2026 Jan","pmid":"41167447","title":"Structure-based drug repurposing and experimental validation of inhibitors targeting LigaseD from Mycobacterium tuberculosis.","journal":"Archives of biochemistry and biophysics"},{"date":"2025 Nov 14","pmid":"41151410","title":"Metabolic reprogramming of hippocampal endothelial cells contributes to blood-brain barrier dysfunction in perioperative neurocognitive disorder.","journal":"Biochemical and biophysical research communications"},{"date":"2025 Sep 24","pmid":"41019617","title":"Insights into Antiviral Candidates against Oropouche Virus: A Molecular Dynamics Study.","journal":"ACS physical chemistry Au"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"discontinued","companyName":"Merck Sharp Dohme","companyId":"merck","modality":"Small molecule","firstApprovalDate":"1996","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-03-13T00:00:00.000Z","mah":"MERCK SHARP DOHME","brand_name_local":null,"application_number":""},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1996-03-13T00:00:00.000Z","mah":"MERCK SHARP DOHME","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1996-03-13T00:00:00.000Z","mah":"MERCK SHARP DOHME","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1996-03-13T00:00:00.000Z","mah":"MERCK SHARP DOHME","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1996-03-13T00:00:00.000Z","mah":"MERCK SHARP DOHME","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1996-03-13T00:00:00.000Z","mah":"MERCK SHARP DOHME","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Crixivan","application_number":"EMEA/H/C/000128"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Crixivan","application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}